Advertisement

best practice onkologie

, Volume 13, Issue 4, pp 214–225 | Cite as

Prophylaxe und Therapie der chemotherapieinduzierten Polyneuropathie

  • Susanne Koeppen
CME
  • 380 Downloads

Zusammenfassung

Die chemotherapieinduzierte periphere Neuropathie (CIPN) ist eine der am stärksten beeinträchtigenden Nebenwirkungen einer Tumorbehandlung mit neurotoxischen Substanzen wie Platinverbindungen, Taxane, Vincaalkaloide, Eribulin und Bortezomib. Zum Schutz der Patienten vor langfristigen Einschränkungen der Funktionsfähigkeit und Lebensqualität wird die frühzeitige Erkennung der CIPN durch Erfassung neuropathischer Symptome vor jedem Behandlungszyklus unter Einbeziehung von Patientenangaben angestrebt. Die oxaliplatinbedingte akute Neurotoxizität und das taxaninduzierte akute Schmerzsyndrom sind prädiktiv für die Entwicklung einer kumulativen peripheren Neurotoxizität. Eine prompte Dosismodifikation der ursächlichen Substanz ermöglicht, eine Unterbrechung oder ein Absetzen der onkologischen Therapie zu vermeiden. Eine pharmakologische CIPN-Prophylaxe ist bislang nicht etabliert. Duloxetin sowie Bewegungstherapie und Balancetraining sind Behandlungsansätze für eine CIPN.

Schlüsselwörter

Chemotherapie-induzierte periphere Neuropathie Neurotoxizität patient-reported outcome measures neuropathischer Schmerz Balance-Training 

Prevention and treatment of chemotherapy-induced peripheral neuropathy

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most disabling side effects of cancer treatment with neurotoxic agents such as platinum compounds, taxanes, vinca-alkaloids, eribulin, and bortezomib. To protect patients from long-term impairments of daily functioning and quality of life, early diagnosis of CIPN via assessment of neuropathic symptoms and patient-reported outcome measures prior to each treatment cycle is desirable. Acute neurotoxicity due to oxaliplatin and taxane-induced acute pain syndrome are predictive for development of cumulative peripheral neurotoxicity. Prompt dose modification of the causal substance can avoid interruption or discontinuation of tumor therapy. Pharmacologic prophylaxis of CIPN has not been established so far. Duloxetine as well as exercise and balance training are promising approaches to CIPN treatment.

Keywords

Chemotherapy-induced peripheral neuropathy Neurotoxicity Patient-reported outcome measures Neuropathic pain Balance training 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

S. Koeppen gibt an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von der Autorin durchgeführten Studien an Menschen oder Tieren.

Literatur

  1. 1.
    Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, Colvin LA, Fallon M (2014) Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain 155(12):2461–2470CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Cliff J, Jorgensen AL, Lord R, Azam F, Cossar L, Carr DF, Pirmohamed M (2017) The molecular genetics of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Crit Rev Oncol Hematol 120:127–140CrossRefPubMedGoogle Scholar
  3. 3.
    Argyriou AA, Bruna J, Genazzani AA, Cavaletti G (2017) Chemotherapy-induced peripheral neurotoxicity: management informed by pharmacogenetics. Nat Rev Neurol 13(8):492–504CrossRefPubMedGoogle Scholar
  4. 4.
    Cavaletti G, Jann S, Pace A, Plasmati R, Siciliano G, Briani C, Cocito D, Padua L, Ghiglione E, Manicone M, Giussani G, Italian NG (2006) Multi-center assessment of the Total Neuropathy Score for chemotherapy-induced peripheral neurotoxicity. J Peripher Nerv Syst 11(2):135–141CrossRefPubMedGoogle Scholar
  5. 5.
    Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY, Hoang-Xuan K, Lanteri-Minet M, Grant R, Huddart R, Moynihan C, Maher J, Lucey R, E. Q. o. L. Group (2005) The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer 41(8):1135–1139CrossRefPubMedGoogle Scholar
  6. 6.
    Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, Chauhan C, Gavin P, Lavino A, Lustberg MB, Paice J, Schneider B, Smith ML, Smith T, Terstriep S, Wagner-Johnston N, Bak K, Loprinzi CL, American Society of Clinical Oncology (2014) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 32(18):1941–1967CrossRefPubMedGoogle Scholar
  7. 7.
    Greenlee H, Hershman DL, Shi Z, Kwan ML, Ergas IJ, Roh JM, Kushi LH (2017) BMI, lifestyle factors and taxane-induced neuropathy in breast cancer patients: the pathways study. J Natl Cancer Inst.  https://doi.org/10.1093/jnci/djw206 PubMedCrossRefGoogle Scholar
  8. 8.
    Beutler AS, Kulkarni AA, Kanwar R, Klein CJ, Therneau TM, Qin R, Banck MS, Boora GK, Ruddy KJ, Wu Y, Smalley RL, Cunningham JM, Le-Lindqwister NA, Beyerlein P, Schroth GP, Windebank AJ, Zuchner S, Loprinzi CL (2014) Sequencing of Charcot-Marie-Tooth disease genes in a toxic polyneuropathy. Ann Neurol 76(5):727–737CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Miltenburg NC, Boogerd W (2014) Chemotherapy-induced neuropathy: a comprehensive survey. Cancer Treat Rev 40(7):872–882CrossRefPubMedGoogle Scholar
  10. 10.
    Brydoy M, Oldenburg J, Klepp O, Bremnes RM, Wist EA, Wentzel-Larsen T, Hauge ER, Dahl O, Fossa SD (2009) Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors. J Natl Cancer Inst 101(24):1682–1695CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Windebank AJ, Grisold W (2008) Chemotherapy-induced neuropathy. J Peripher Nerv Syst 13(1):27–46CrossRefPubMedGoogle Scholar
  12. 12.
    Pachman DR, Qin R, Seisler DK, Smith EM, Beutler AS, Ta LE, Lafky JM, Wagner-Johnston ND, Ruddy KJ, Dakhil S, Staff NP, Grothey A, Loprinzi CL (2015) Clinical course of oxaliplatin-induced neuropathy: results from the randomized phase III trial N08CB (alliance). J Clin Oncol 33(30):3416–3422CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Park SB, Lin CS, Krishnan AV, Goldstein D, Friedlander ML, Kiernan MC (2011) Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. Oncologist 16(5):708–716CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Argyriou AA, Briani C, Cavaletti G, Bruna J, Alberti P, Velasco R, Lonardi S, Cortinovis D, Cazzaniga M, Campagnolo M, Santos C, Kalofonos HP (2013) Advanced age and liability to oxaliplatin-induced peripheral neuropathy: post hoc analysis of a prospective study. Eur J Neurol 20(5):788–794CrossRefPubMedGoogle Scholar
  15. 15.
    Uwah AN, Ackler J, Leighton JC Jr., Pomerantz S, Tester W (2012) The effect of diabetes on oxaliplatin-induced peripheral neuropathy. Clin Colorectal Cancer 11(4):275–279CrossRefPubMedGoogle Scholar
  16. 16.
    Glimelius B, Manojlovic N, Pfeiffer P, Mosidze B, Kurteva G, Karlberg M, Mahalingam D, Buhl Jensen P, Kowalski J, Bengtson M, Nittve M, Nasstrom J (2018) Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx((R))): a placebo-controlled randomised phase II study (PLIANT). Acta Oncol 57(3):393–402CrossRefPubMedGoogle Scholar
  17. 17.
    Brozou V, Vadalouca A, Zis P (2017) Pain in platin-induced Neuropathies: a systematic review and meta-analysis. Pain Ther.  https://doi.org/10.1007/s40122-017-0092-3 PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Verstappen CC, Koeppen S, Heimans JJ, Huijgens PC, Scheulen ME, Strumberg D, Kiburg B, Postma TJ (2005) Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening. Neurology 64(6):1076–1077CrossRefPubMedGoogle Scholar
  19. 19.
    Argyriou AA, Kyritsis AP, Makatsoris T, Kalofonos HP (2014) Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature. Cancer Manag Res 6:135–147CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Liu Y, Ye G, Yan D, Zhang L, Fan F, Feng J (2017) Role of nab-paclitaxel in metastatic breast cancer: a meta-analysis of randomized clinical trials. Oncotarget 8(42):72950–72958PubMedPubMedCentralGoogle Scholar
  21. 21.
    Kus T, Aktas G, Kalender ME, Sevinc A, Kul S, Suner A, Ulker E, Camci C (2016) Taxane-induced peripheral sensorial neuropathy in cancer patients is associated with duration of diabetes mellitus: a single-center retrospective study. Support Care Cancer 24(3):1175–1179CrossRefPubMedGoogle Scholar
  22. 22.
    Loprinzi CL, Reeves BN, Dakhil SR, Sloan JA, Wolf SL, Burger KN, Kamal A, Le-Lindqwister NA, Soori GS, Jaslowski AJ, Novotny PJ, Lachance DH (2011) Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J Clin Oncol 29(11):1472–1478CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Reeves BN, Dakhil SR, Sloan JA, Wolf SL, Burger KN, Kamal A, Le-Lindqwister NA, Soori GS, Jaslowski AJ, Kelaghan J, Novotny PJ, Lachance DH, Loprinzi CL (2012) Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy: North Central Cancer Treatment Group trial N08C1. Cancer 118(20):5171–5178CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Cortes J, O’Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Dieras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C, E. investigators (2011) Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 377(9769):914–923CrossRefPubMedGoogle Scholar
  25. 25.
    Richardson PG, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Blade J, Boccadoro M, Cavenagh JD, Boral AL, Esseltine DL, Wen PY, Amato AA, Anderson KC, San Miguel J (2009) Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol 144(6):895–903CrossRefPubMedGoogle Scholar
  26. 26.
    Bringhen S, Larocca A, Rossi D, Cavalli M, Genuardi M, Ria R, Gentili S, Patriarca F, Nozzoli C, Levi A, Guglielmelli T, Benevolo G, Callea V, Rizzo V, Cangialosi C, Musto P, De Rosa L, Liberati AM, Grasso M, Falcone AP, Evangelista A, Cavo M, Gaidano G, Boccadoro M, Palumbo A (2010) Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 116(23):4745–4753CrossRefPubMedGoogle Scholar
  27. 27.
    Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, Rekhtman G, Masliak Z, Robak T, Shubina A, Arnulf B, Kropff M, Cavet J, Esseltine DL, Feng H, Girgis S, van de Velde H, Deraedt W, Harousseau JL (2011) Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 12(5):431–440CrossRefPubMedGoogle Scholar
  28. 28.
    Palumbo A, Gay F (2009) How to treat elderly patients with multiple myeloma: combination of therapy or sequencing. Hematology Am Soc Hematol Educ Program 2009:566–577.  https://doi.org/10.1182/asheducation-2009.1.566 CrossRefGoogle Scholar
  29. 29.
    Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hajek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosinol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarer A, Minuk L, Masszi T, Karamanesht I, Offidani M, Hungria V, Spencer A, Orlowski RZ, Gillenwater HH, Mohamed N, Feng S, Chng WJ, E. Investigators (2016) Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol 17(1):27–38CrossRefPubMedGoogle Scholar
  30. 30.
    Hajek R, Masszi T, Petrucci MT, Palumbo A, Rosinol L, Nagler A, Yong KL, Oriol A, Minarik J, Pour L, Dimopoulos MA, Maisnar V, Rossi D, Kasparu H, Van Droogenbroeck J, Yehuda DB, Hardan I, Jenner M, Calbecka M, David M, de la Rubia J, Drach J, Gasztonyi Z, Gornik S, Leleu X, Munder M, Offidani M, Zojer N, Rajangam K, Chang YL, San-Miguel JF, Ludwig H (2017) A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). Leukemia 31(1):107–114CrossRefPubMedGoogle Scholar
  31. 31.
    Richardson PG, Baz R, Wang M, Jakubowiak AJ, Laubach JP, Harvey RD, Talpaz M, Berg D, Liu G, Yu J, Gupta N, Di Bacco A, Hui AM, Lonial S (2014) Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. Blood 124(7):1038–1046CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar S, Touzeau C, Buadi FK, Laubach JP, Berg DT, Lin J, Di Bacco A, Hui AM, van de Velde H, Richardson PG, T.-M. S. Group (2016) Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med 374(17):1621–1634CrossRefPubMedGoogle Scholar
  33. 33.
    Kumar S, Moreau P, Hari P, Mateos MV, Ludwig H, Shustik C, Masszi T, Spencer A, Hajek R, Romeril K, Avivi I, Liberati AM, Minnema MC, Einsele H, Lonial S, Berg D, Lin J, Gupta N, Esseltine DL, Richardson PG (2017) Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. Br J Haematol 178(4):571–582CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Cavaletti G, Beronio A, Reni L, Ghiglione E, Schenone A, Briani C, Zara G, Cocito D, Isoardo G, Ciaramitaro P, Plasmati R, Pastorelli F, Frigo M, Piatti M, Carpo M (2004) Thalidomide sensory neurotoxicity: a clinical and neurophysiologic study. Neurology 62(12):2291–2293CrossRefPubMedGoogle Scholar
  35. 35.
    Palumbo A, Davies F, Kropff M, Blade J, Delforge M, Leal da Costa F, Garcia Sanz R, Schey S, Facon T, Morgan G, Moreau P (2010) Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma. Ann Hematol 89(8):803–811CrossRefPubMedGoogle Scholar
  36. 36.
    Delforge M, Blade J, Dimopoulos MA, Facon T, Kropff M, Ludwig H, Palumbo A, Van Damme P, San-Miguel JF, Sonneveld P (2010) Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol 11(11):1086–1095CrossRefPubMedGoogle Scholar
  37. 37.
    Hanaizi Z, Flores B, Hemmings R, Camarero J, Sancho-Lopez A, Salmonson T, Gisselbrecht C, Laane E, Pignatti F (2015) The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use. Oncologist 20(3):329–334CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Moreau P, Dimopoulos MA, Richardson PG, Siegel DS, Cavo M, Corradini P, Weisel K, Delforge M, O’Gorman P, Song K, Chen C, Bahlis N, Oriol A, Hansson M, Kaiser M, Anttila P, Raymakers R, Joao C, Cook G, Sternas L, Biyukov T, Slaughter A, Hong K, Herring J, Yu X, Zaki M, San-Miguel J (2017) Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: a pooled analysis. Eur J Haematol 99(3):199–206CrossRefPubMedGoogle Scholar
  39. 39.
    Greig SL (2016) Panobinostat: a review in relapsed or refractory multiple myeloma. Target Oncol 11(1):107–114CrossRefPubMedGoogle Scholar
  40. 40.
    San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Gunther A, Nakorn TN, Siritanaratkul N, Corradini P, Chuncharunee S, Lee JJ, Schlossman RL, Shelekhova T, Yong K, Tan D, Numbenjapon T, Cavenagh JD, Hou J, LeBlanc R, Nahi H, Qiu L, Salwender H, Pulini S, Moreau P, Warzocha K, White D, Blade J, Chen W, de la Rubia J, Gimsing P, Lonial S, Kaufman JL, Ocio EM, Veskovski L, Sohn SK, Wang MC, Lee JH, Einsele H, Sopala M, Corrado C, Bengoudifa BR, Binlich F, Richardson PG (2014) Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol 15(11):1195–1206CrossRefPubMedGoogle Scholar
  41. 41.
    Kleckner IR, Kamen C, Gewandter JS, Mohile NA, Heckler CE, Culakova E, Fung C, Janelsins MC, Asare M, Lin PJ, Reddy PS, Giguere J, Berenberg J, Kesler SR, Mustian KM (2017) Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial. Support Care Cancer 26(4):1019.  https://doi.org/10.1007/s00520-017-4013-0 CrossRefPubMedGoogle Scholar
  42. 42.
    Schwenk M, Grewal GS, Holloway D, Muchna A, Garland L, Najafi B (2016) Interactive sensor-based balance training in older cancer patients with chemotherapy-induced peripheral neuropathy: a randomized controlled trial. Gerontology 62(5):553–563CrossRefPubMedGoogle Scholar
  43. 43.
    Prinsloo S, Novy D, Driver L, Lyle R, Ramondetta L, Eng C, McQuade J, Lopez G, Cohen L (2017) Randomized controlled trial of neurofeedback on chemotherapy-induced peripheral neuropathy: a pilot study. Cancer 123(11):1989–1997CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Greenlee H, Crew KD, Capodice J, Awad D, Buono D, Shi Z, Jeffres A, Wyse S, Whitman W, Trivedi MS, Kalinsky K, Hershman DL (2016) Randomized sham-controlled pilot trial of weekly electro-acupuncture for the prevention of taxane-induced peripheral neuropathy in women with early stage breast cancer. Breast Cancer Res Treat 156(3):453–464CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, Bressler LR, Fadul CE, Knox C, Le-Lindqwister N, Gilman PB, Shapiro CL, O. Alliance for Clinical Trials (2013) Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 309(13):1359–1367CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, Gilron I, Haanpaa M, Hansson P, Jensen TS, Kamerman PR, Lund K, Moore A, Raja SN, Rice AS, Rowbotham M, Sena E, Siddall P, Smith BH, Wallace M (2015) Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol 14(2):162–173CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Moulin D, Boulanger A, Clark AJ, Clarke H, Dao T, Finley GA, Furlan A, Gilron I, Gordon A, Morley-Forster PK, Sessle BJ, Squire P, Stinson J, Taenzer P, Velly A, Ware MA, Weinberg EL, Williamson OD, S. Canadian Pain (2014) Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manag 19(6):328–335CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Barton DL, Wos EJ, Qin R, Mattar BI, Green NB, Lanier KS, Bearden JD 3rd, Kugler JW, Hoff KL, Reddy PS, Rowland KM Jr., Riepl M, Christensen B, Loprinzi CL (2011) A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. Support Care Cancer 19(6):833–841CrossRefPubMedGoogle Scholar
  49. 49.
    Gewandter JS, Mohile SG, Heckler CE, Ryan JL, Kirshner JJ, Flynn PJ, Hopkins JO, Morrow GR (2014) A phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study of 462 cancer survivors. Support Care Cancer 22(7):1807–1814CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Fallon MT, Storey DJ, Krishan A, Weir CJ, Mitchell R, Fleetwood-Walker SM, Scott AC, Colvin LA (2015) Cancer treatment-related neuropathic pain: proof of concept study with menthol—a TRPM8 agonist. Support Care Cancer 23(9):2769–2777CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Durand JP, Deplanque G, Montheil V, Gornet JM, Scotte F, Mir O, Cessot A, Coriat R, Raymond E, Mitry E, Herait P, Yataghene Y, Goldwasser F (2012) Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol 23(1):200–205CrossRefPubMedGoogle Scholar
  52. 52.
    Zimmerman C, Atherton PJ, Pachman D, Seisler D, Wagner-Johnston N, Dakhil S, Lafky JM, Qin R, Grothey A, Loprinzi CL (2016) MC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy. Support Care Cancer 24(3):1071–1078CrossRefPubMedGoogle Scholar
  53. 53.
    Albers JW, Chaudhry V, Cavaletti G, Donehower RC (2014) Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev.  https://doi.org/10.1002/14651858.CD005228.pub3 PubMedCrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Klinik für NeurologieUniversitätsklinikum EssenEssenDeutschland

Personalised recommendations